Modelling and sample size reestimation for longitudinal count data with incomplete follow up.


Journal

Statistical methods in medical research
ISSN: 1477-0334
Titre abrégé: Stat Methods Med Res
Pays: England
ID NLM: 9212457

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 22 6 2017
medline: 2 5 2020
entrez: 22 6 2017
Statut: ppublish

Résumé

We consider modelling and inference as well as sample size estimation and reestimation for clinical trials with longitudinal count data as outcomes. Our approach is general but is rooted in design and analysis of multiple sclerosis trials where lesion counts obtained by magnetic resonance imaging are important endpoints. We adopt a binomial thinning model that allows for correlated counts with marginal Poisson or negative binomial distributions. Methods for sample size planning and blinded sample size reestimation for randomised controlled clinical trials with such outcomes are developed. The models and approaches are applicable to data with incomplete observations. A simulation study is conducted to assess the effectiveness of sample size estimation and blinded sample size reestimation methods. Sample sizes attained through these procedures are shown to maintain the desired study power without inflating the type I error. Data from a recent trial in patients with secondary progressive multiple sclerosis illustrate the modelling approach.

Identifiants

pubmed: 28633609
doi: 10.1177/0962280217715664
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-133

Auteurs

Thomas Asendorf (T)

1 Department of Medical Statistics, University Medical Center Göttingen, Germany.

Robin Henderson (R)

2 School of Mathematics and Statistics, University of Newcastle, UK.

Heinz Schmidli (H)

3 Statistical Methodology, Novartis Pharma AG, Switzerland.

Tim Friede (T)

1 Department of Medical Statistics, University Medical Center Göttingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH